Afasci, Inc.
Burlingame, CA Doing business as Afasci Inc.
- UEI
- UGMEBNM4WSL6
- CAGE
- 43M05
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2633 Martinez Dr, Burlingame, CA 94010, USA
- Website
- afasci.com
- Founded
- 2003
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a novel medication for alcohol use disorder with an active IND dual inhibitor of t-type calcium channel… | National Institute on Alcohol Abuse and Alcoholism | $982,702 | |
| Clinical phase i trials on an IND single molecule dual inhibitor of CAV3 channels and soluble epoxide hydrolase for… | National Institute of Neurological Disorders and Stroke | $6,149,724 | |
| Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of CAV3 channel and soluble epoxide… | National Institute on Drug Abuse | $319,547 | |
| Discovering girk channel direct activator as a novel chronic insomnia therapeutic | National Heart Lung and Blood Institute | $399,429 | |
| Sample-free onsite detection of cocaine using microneedles via laser-treated skin | National Institute on Drug Abuse | $223,633 |
About Afasci, Inc.
Afasci, Inc., doing business as Afasci Research Laboratories, is a San Francisco Bay Area biotech company that conducts research and development in biotechnology and therapeutics. Afasci has not received any prime federal contract awards. The company received one federal contract subaward from SRI International to conduct a rodent pharmacokinetic study.
Through federal grants, Afasci has focused on developing medications to treat substance use disorders and neuropathic pain. This includes a $483,851 cooperative agreement from the National Institute on Alcohol Abuse and Alcoholism to develop a novel medication for alcohol use disorder. Afasci also received a $4,499,793 project grant from the National Institute of Neurological Disorders and Stroke to conduct clinical Phase I trials on AFA-281, a non-opioid medication for neuropathic pain. Additionally, the company was awarded a $319,547 project grant from the National Institute on Drug Abuse to develop a treatment for cocaine use disorder using its investigational new drug AFA-281. Afasci has also received one federal grant subaward from the University of Nebraska related to discovery and evaluation of pain medications.
Quick answers
What is Afasci, Inc.'s UEI?
Afasci, Inc.'s Unique Entity ID (UEI) in SAM.gov is UGMEBNM4WSL6.
What is Afasci, Inc.'s CAGE code?
Afasci, Inc.'s CAGE code is 43M05.
What is Afasci, Inc.'s primary NAICS code?
Afasci, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Afasci, Inc. located?
Afasci, Inc.'s physical address in SAM.gov is 2633 Martinez Dr, Burlingame, CA 94010, USA.
Is Afasci, Inc. registered in SAM.gov?
Yes. Afasci, Inc.'s SAM.gov registration is active through September 17, 2027.
What is Afasci, Inc.'s most recent federal award?
Afasci, Inc.'s most recent federal grant award is Development of a novel medication for alcohol use disorder with an active IND dual inhibitor of t-type calcium channel… (U43AA031391), from National Institute on Alcohol Abuse and Alcoholism, on September 25, 2023.
On GovTribe
See Afasci, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors